Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 149 entries
Sorted by: Best Match Show Resources per page
Dietary sodium and target organ damage in essential hypertension.

Current hypertension reports

Hollenberg NK.
PMID: 12669712
Curr Hypertens Rep. 2003 Feb;5(1):8. doi: 10.1007/s11906-003-0004-2.

No abstract available.

Cite
Hollenberg NK. Dietary sodium and target organ damage in essential hypertension. Curr Hypertens Rep. 2003;5(1):8doi: 10.1007/s11906-003-0004-2.
Hollenberg, N. K. (2003). Dietary sodium and target organ damage in essential hypertension. Current hypertension reports, 5(1), 8. https://doi.org/10.1007/s11906-003-0004-2
Hollenberg, Norman K. "Dietary sodium and target organ damage in essential hypertension." Current hypertension reports vol. 5,1 (2003): 8. doi: https://doi.org/10.1007/s11906-003-0004-2
Hollenberg NK. Dietary sodium and target organ damage in essential hypertension. Curr Hypertens Rep. 2003 Feb;5(1):8. doi: 10.1007/s11906-003-0004-2. PMID: 12669712.
Copy Download .nbib Format: NLM
Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin.

Current hypertension reports

Hollenberg NK.
PMID: 12696559
Curr Hypertens Rep. 2003 Apr;5(2):98-9. doi: 10.1007/s11906-003-0063-4.

No abstract available.

Cite
Hollenberg NK. Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin. Curr Hypertens Rep. 2003;5(2):98-9doi: 10.1007/s11906-003-0063-4.
Hollenberg, N. K. (2003). Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin. Current hypertension reports, 5(2), 98-9. https://doi.org/10.1007/s11906-003-0063-4
Hollenberg, Norman K. "Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin." Current hypertension reports vol. 5,2 (2003): 98-9. doi: https://doi.org/10.1007/s11906-003-0063-4
Hollenberg NK. Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin. Curr Hypertens Rep. 2003 Apr;5(2):98-9. doi: 10.1007/s11906-003-0063-4. PMID: 12696559.
Copy Download .nbib Format: NLM
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

Current hypertension reports

Ruschitzka FT.
PMID: 12530936
Curr Hypertens Rep. 2003 Feb;5(1):57-8. doi: 10.1007/s11906-003-0011-3.

No abstract available.

Cite
Ruschitzka FT. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Curr Hypertens Rep. 2003;5(1):57-8doi: 10.1007/s11906-003-0011-3.
Ruschitzka, F. T. (2003). Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Current hypertension reports, 5(1), 57-8. https://doi.org/10.1007/s11906-003-0011-3
Ruschitzka, Frank T. "Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)." Current hypertension reports vol. 5,1 (2003): 57-8. doi: https://doi.org/10.1007/s11906-003-0011-3
Ruschitzka FT. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Curr Hypertens Rep. 2003 Feb;5(1):57-8. doi: 10.1007/s11906-003-0011-3. PMID: 12530936.
Copy Download .nbib Format: NLM
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.

Current hypertension reports

Hollenberg NK.
PMID: 14524367
Curr Hypertens Rep. 2003 Jun;5(3):183-5. doi: 10.1007/s11906-003-0018-9.

No abstract available.

Cite
Hollenberg NK. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Curr Hypertens Rep. 2003;5(3):183-5doi: 10.1007/s11906-003-0018-9.
Hollenberg, N. K. (2003). The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Current hypertension reports, 5(3), 183-5. https://doi.org/10.1007/s11906-003-0018-9
Hollenberg, Norman K. "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic." Current hypertension reports vol. 5,3 (2003): 183-5. doi: https://doi.org/10.1007/s11906-003-0018-9
Hollenberg NK. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Curr Hypertens Rep. 2003 Jun;5(3):183-5. doi: 10.1007/s11906-003-0018-9. PMID: 14524367.
Copy Download .nbib Format: NLM
Direct renin inhibitors: where will they fit in for antihypertensive treatment?.

Current hypertension reports

Weir MR.
PMID: 18177585
Curr Hypertens Rep. 2007 Nov;9(5):389-91. doi: 10.1007/s11906-007-0071-x.

No abstract available.

Cite
Weir MR. Direct renin inhibitors: where will they fit in for antihypertensive treatment?. Curr Hypertens Rep. 2007;9(5):389-91doi: 10.1007/s11906-007-0071-x.
Weir, M. R. (2007). Direct renin inhibitors: where will they fit in for antihypertensive treatment?. Current hypertension reports, 9(5), 389-91. https://doi.org/10.1007/s11906-007-0071-x
Weir, Matthew R. "Direct renin inhibitors: where will they fit in for antihypertensive treatment?." Current hypertension reports vol. 9,5 (2007): 389-91. doi: https://doi.org/10.1007/s11906-007-0071-x
Weir MR. Direct renin inhibitors: where will they fit in for antihypertensive treatment?. Curr Hypertens Rep. 2007 Nov;9(5):389-91. doi: 10.1007/s11906-007-0071-x. PMID: 18177585.
Copy Download .nbib Format: NLM
Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect.

Current hypertension reports

Mansour G, Mansour J.
PMID: 18367012
Curr Hypertens Rep. 2007 Dec;9(6):489-90. doi: 10.1007/s11906-007-0089-0.

No abstract available.

Cite
Mansour G, Mansour J. Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect. Curr Hypertens Rep. 2007;9(6):489-90doi: 10.1007/s11906-007-0089-0.
Mansour, G., & Mansour, J. (2007). Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect. Current hypertension reports, 9(6), 489-90. https://doi.org/10.1007/s11906-007-0089-0
Mansour, George, and Mansour, Janette. "Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect." Current hypertension reports vol. 9,6 (2007): 489-90. doi: https://doi.org/10.1007/s11906-007-0089-0
Mansour G, Mansour J. Cilnidipine in management of patients with uncontrolled hypertension and white-coat effect. Curr Hypertens Rep. 2007 Dec;9(6):489-90. doi: 10.1007/s11906-007-0089-0. PMID: 18367012.
Copy Download .nbib Format: NLM
Rimonabant--a new weapon in the war on obesity.

Current hypertension reports

Taegtmeyer H, Lux TR.
PMID: 17087852
Curr Hypertens Rep. 2006 Dec;8(6):441-2. doi: 10.1007/s11906-006-0019-6.

No abstract available.

Cite
Taegtmeyer H, Lux TR. Rimonabant--a new weapon in the war on obesity. Curr Hypertens Rep. 2006;8(6):441-2doi: 10.1007/s11906-006-0019-6.
Taegtmeyer, H., & Lux, T. R. (2006). Rimonabant--a new weapon in the war on obesity. Current hypertension reports, 8(6), 441-2. https://doi.org/10.1007/s11906-006-0019-6
Taegtmeyer, Heinrich, and Lux, Thomas R. "Rimonabant--a new weapon in the war on obesity." Current hypertension reports vol. 8,6 (2006): 441-2. doi: https://doi.org/10.1007/s11906-006-0019-6
Taegtmeyer H, Lux TR. Rimonabant--a new weapon in the war on obesity. Curr Hypertens Rep. 2006 Dec;8(6):441-2. doi: 10.1007/s11906-006-0019-6. PMID: 17087852.
Copy Download .nbib Format: NLM
Clinical trials report. VALIANT: another milestone for angiotensin receptor blockers.

Current hypertension reports

Siragy HM.
PMID: 15257858
Curr Hypertens Rep. 2004 Aug;6(4):255-6. doi: 10.1007/s11906-004-0018-4.

No abstract available.

Cite
Siragy HM. Clinical trials report. VALIANT: another milestone for angiotensin receptor blockers. Curr Hypertens Rep. 2004;6(4):255-6doi: 10.1007/s11906-004-0018-4.
Siragy, H. M. (2004). Clinical trials report. VALIANT: another milestone for angiotensin receptor blockers. Current hypertension reports, 6(4), 255-6. https://doi.org/10.1007/s11906-004-0018-4
Siragy, Helmy M. "Clinical trials report. VALIANT: another milestone for angiotensin receptor blockers." Current hypertension reports vol. 6,4 (2004): 255-6. doi: https://doi.org/10.1007/s11906-004-0018-4
Siragy HM. Clinical trials report. VALIANT: another milestone for angiotensin receptor blockers. Curr Hypertens Rep. 2004 Aug;6(4):255-6. doi: 10.1007/s11906-004-0018-4. PMID: 15257858.
Copy Download .nbib Format: NLM
Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension.

Current hypertension reports

Weber MA, Sica DA.
PMID: 15257863
Curr Hypertens Rep. 2004 Aug;6(4):291-2. doi: 10.1007/s11906-004-0023-7.

No abstract available.

Cite
Weber MA, Sica DA. Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. Curr Hypertens Rep. 2004;6(4):291-2doi: 10.1007/s11906-004-0023-7.
Weber, M. A., & Sica, D. A. (2004). Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. Current hypertension reports, 6(4), 291-2. https://doi.org/10.1007/s11906-004-0023-7
Weber, Michael A, and Sica, Domenic A. "Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension." Current hypertension reports vol. 6,4 (2004): 291-2. doi: https://doi.org/10.1007/s11906-004-0023-7
Weber MA, Sica DA. Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. Curr Hypertens Rep. 2004 Aug;6(4):291-2. doi: 10.1007/s11906-004-0023-7. PMID: 15257863.
Copy Download .nbib Format: NLM
Renal damage in primary aldosteronism: results of the PAPY study.

Current hypertension reports

Tuck ML, Corry DB.
PMID: 17442217
Curr Hypertens Rep. 2007 Apr;9(2):87-9. doi: 10.1007/s11906-007-0016-4.

No abstract available.

Cite
Tuck ML, Corry DB. Renal damage in primary aldosteronism: results of the PAPY study. Curr Hypertens Rep. 2007;9(2):87-9doi: 10.1007/s11906-007-0016-4.
Tuck, M. L., & Corry, D. B. (2007). Renal damage in primary aldosteronism: results of the PAPY study. Current hypertension reports, 9(2), 87-9. https://doi.org/10.1007/s11906-007-0016-4
Tuck, Michael L, and Corry, Dalila B. "Renal damage in primary aldosteronism: results of the PAPY study." Current hypertension reports vol. 9,2 (2007): 87-9. doi: https://doi.org/10.1007/s11906-007-0016-4
Tuck ML, Corry DB. Renal damage in primary aldosteronism: results of the PAPY study. Curr Hypertens Rep. 2007 Apr;9(2):87-9. doi: 10.1007/s11906-007-0016-4. PMID: 17442217.
Copy Download .nbib Format: NLM
Clinical trials report. Good news and bad news: now the bad news.

Current hypertension reports

Kaplan NM.
PMID: 16157069
Curr Hypertens Rep. 2005 Oct;7(5):310-1. doi: 10.1007/s11906-005-0061-9.

No abstract available.

Cite
Kaplan NM. Clinical trials report. Good news and bad news: now the bad news. Curr Hypertens Rep. 2005;7(5):310-1doi: 10.1007/s11906-005-0061-9.
Kaplan, N. M. (2005). Clinical trials report. Good news and bad news: now the bad news. Current hypertension reports, 7(5), 310-1. https://doi.org/10.1007/s11906-005-0061-9
Kaplan, Norman M. "Clinical trials report. Good news and bad news: now the bad news." Current hypertension reports vol. 7,5 (2005): 310-1. doi: https://doi.org/10.1007/s11906-005-0061-9
Kaplan NM. Clinical trials report. Good news and bad news: now the bad news. Curr Hypertens Rep. 2005 Oct;7(5):310-1. doi: 10.1007/s11906-005-0061-9. PMID: 16157069.
Copy Download .nbib Format: NLM
Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease.

Current hypertension reports

Bakris G.
PMID: 16157078
Curr Hypertens Rep. 2005 Oct;7(5):358-9.

No abstract available.

Cite
Bakris G. Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Curr Hypertens Rep. 2005;7(5):358-9
Bakris, G. (2005). Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Current hypertension reports, 7(5), 358-9.
Bakris, George. "Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease." Current hypertension reports vol. 7,5 (2005): 358-9.
Bakris G. Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Curr Hypertens Rep. 2005 Oct;7(5):358-9. PMID: 16157078.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 149 entries